Westend Capital Management LLC Purchases Shares of 16,393 Eli Lilly and Company $LLY

Key Points

• Westend Capital Management acquired 16,393 shares of Eli Lilly (NYSE:LLY) in Q4 worth about $17.62 million, making LLY roughly 4.9% of its portfolio and its fifth-largest holding.
• Recent catalysts — the FDA approved Lilly’s oral GLP‑1 obesity pill Foundayo and Lilly agreed to buy Centessa (initially ~$6.3B), driving bullish options activity and boosting growth expectations.
• Fundamentals and analyst view — Lilly beat quarterly revenue and EPS estimates, set FY2026 EPS guidance of 33.50–35.00, and carries an average analyst target around $1,221 with most analysts rating the stock buy/moderate buy.

Westend Capital Management LLC acquired a new position in Eli Lilly and Company (NYSE:LLY - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 16,393 shares of the company's stock, valued at approximately $17,617,000. Eli Lilly and Company accounts for approximately 4.9% of Westend Capital Management LLC's portfolio, making the stock its 5th biggest position.

Other institutional investors and hedge funds have also modified their holdings of the company. Vermillion & White Wealth Management Group LLC boosted its stake in Eli Lilly and Company by 84.2% during the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company's stock worth $27,000 after buying an additional 16 shares in the last quarter. Evolution Wealth Management Inc. bought a new stake in Eli Lilly and Company in the second quarter valued at about $29,000. Steph & Co. raised its position in Eli Lilly and Company by 290.0% in the third quarter. Steph & Co. now owns 39 shares of the company's stock worth $30,000 after purchasing an additional 29 shares in the last quarter. 10Elms LLP lifted its holdings in shares of Eli Lilly and Company by 33.3% during the third quarter. 10Elms LLP now owns 40 shares of the company's stock valued at $31,000 after acquiring an additional 10 shares during the period. Finally, Miller Global Investments LLC acquired a new position in shares of Eli Lilly and Company in the 4th quarter worth approximately $33,000. 82.53% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. Berenberg Bank increased their price objective on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a "hold" rating in a report on Thursday, February 19th. CICC Research upped their price target on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a "neutral" rating in a research note on Wednesday, February 11th. Jefferies Financial Group set a $1,300.00 price objective on Eli Lilly and Company and gave the stock a "buy" rating in a research note on Friday, March 13th. Zacks Research lowered Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Friday, January 30th. Finally, UBS Group reaffirmed a "buy" rating on shares of Eli Lilly and Company in a research report on Wednesday, March 18th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $1,221.26.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approves Foundayo (orforglipron), Lilly’s once‑daily oral GLP‑1 for obesity — expands the company’s weight‑loss franchise with an easy‑to‑scale pill that the company plans to sell via LillyDirect (low advertised self‑pay price and payer coverage could accelerate adoption). Lilly's weight-loss pill wins US approval (Reuters)
• Positive Sentiment: Lilly agreed to buy Centessa (initial ~$6.3B, up to ~$7.8B with milestones), broadening into sleep‑wake and narcolepsy assets — strategic diversification that reduces reliance on GLP‑1 revenue and bolsters mid‑term growth optionality. Eli Lilly to Buy Centessa (CNBC)
• Positive Sentiment: Unusually large call‑option volume and targeted bullish trades around LLY indicate investor enthusiasm and short‑term upside conviction following the FDA approval and M&A news. This derivatives activity can amplify near‑term price moves. Options Traders Pick Up Pharma Stock After Eli Lilly Buyout (Yahoo)
• Neutral Sentiment: Competitive dynamics: Novo Nordisk is responding (subscription pricing, product tweaks) and remains a formidable rival in GLP‑1s — Foundayo’s approval intensifies the duel but outcomes depend on clinical preference, pricing, and payer decisions. Wegovy vs. Foundayo (TipRanks)
• Negative Sentiment: Policy risk: Lilly’s CEO publicly opposed codifying the Trump administration’s Most Favored Nations drug‑pricing deals into law — signals potential tension with government pricing initiatives that could affect future pricing/reimbursement. Lilly opposes MFN codification (CNBC)
• Negative Sentiment: Deal scrutiny: a law firm has opened an investor probe into the Centessa sale price/process — potential legal or shareholder hurdles could slow closing or create contingencies tied to the transaction. Centessa investor alert (BusinessWire)

Eli Lilly and Company Price Performance

NYSE:LLY opened at $955.45 on Thursday. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,133.95. The company has a market cap of $902.73 billion, a P/E ratio of 41.63, a P/E/G ratio of 1.07 and a beta of 0.51. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. The stock's 50-day simple moving average is $999.28 and its 200 day simple moving average is $966.87.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, beating the consensus estimate of $7.48 by $0.06. The firm had revenue of $19.29 billion during the quarter, compared to analysts' expectations of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business's quarterly revenue was up 42.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.